We are live on ! Find out more
TBI

Trueblue

172 hedge funds and large institutions have $605M invested in Trueblue in 2022 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 70 increasing their positions, 60 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more repeat investments, than reductions

Existing positions increased: 70 | Existing positions reduced: 60

5% more capital invested

Capital invested by funds: $576M → $605M (+$29.6M)

0.37% more ownership

Funds ownership: 96.68%97.06% (+0.37%)

0% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 19

1% less funds holding

Funds holding: 173172 (-1)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $91K

Holders
172
Holders Change
-1
Holders Change %
-0.58%
% of All Funds
2.96%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
19
Increased
70
Reduced
60
Closed
19
Calls
Puts
$91K
Net Calls
-$91K
Net Calls Change
-$91K

TBI Hedge Fund Activity: Q3 2022 in Review

172 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Trueblue (TBI) for Q3 2022, worth a combined $605M — up 5.1% from $576M a quarter earlier.

Fund positioning in TBI was balanced in Q3 2022: 19 funds opened new positions, 19 closed out, 70 added to existing stakes and 60 trimmed.

The largest buyer was Pzena Investment Management, adding an estimated $8.78M. The largest seller was Invenomic Capital Management, exiting entirely with an estimated $6.22M sold.

  • 172 institutional investors held Trueblue (TBI) as of Q3 2022, down from 173 in Q2 2022.
  • Funds reported $605M of Trueblue stock for Q3 2022, up 5.1% quarter-over-quarter.
  • 19 funds opened new Trueblue positions in Q3 2022 and 19 closed out, a net change of 0 holders.
  • The largest Trueblue buyer in Q3 2022 was Pzena Investment Management, an estimated $8.78M added.
  • The largest Trueblue seller in Q3 2022 was Invenomic Capital Management, an estimated $6.22M sold.

Based on aggregated 13F filings for Q3 2022.